key: cord-1005039-zttdwnv7
authors: Pecoraro, Valentina; Negro, Antonella; Pirotti, Tommaso; Trenti, Tommaso
title: Estimate false‐negative RT‐PCR rates for SARS‐CoV‐2. A systematic review and meta‐analysis
date: 2021-12-05
journal: Eur J Clin Invest
DOI: 10.1111/eci.13706
sha: 5e6b2d8b0576770d5e5b1ee491142f4a28ac0e64
doc_id: 1005039
cord_uid: zttdwnv7

BACKGROUND: Molecular‐based tests used to identify symptomatic or asymptomatic patients infected by SARS‐CoV‐2 are characterized by high specificity but scarce sensitivity, generating false‐negative results. We aimed to estimate, through a systematic review of the literature, the rate of RT‐PCR false negatives at initial testing for COVID‐19. METHODS: We systematically searched Pubmed, Embase and CENTRAL as well as a list of reference literature. We included observational studies that collected samples from respiratory tract to detect SARS‐CoV‐2 RNA using RT‐PCR, reporting the number of false‐negative subjects and the number of final patients with a COVID‐19 diagnosis. Reported rates of false negatives were pooled in a meta‐analysis as appropriate. We assessed the risk of bias of included studies and graded the quality of evidence according to the GRADE method. All information in this article is current up to February 2021. RESULTS: We included 32 studies, enrolling more than 18,000 patients infected by SARS‐CoV‐2. The overall false‐negative rate was 0.12 (95%CI from 0.10 to 0.14) with very low certainty of evidence. The impact of misdiagnoses was estimated according to disease prevalence; a range between 2 and 58/1,000 subjects could be misdiagnosed with a disease prevalence of 10%, increasing to 290/1,000 misdiagnosed subjects with a disease prevalence of 50%. CONCLUSIONS: This systematic review showed that up to 58% of COVID‐19 patients may have initial false‐negative RT‐PCR results, suggesting the need to implement a correct diagnostic strategy to correctly identify suspected cases, thereby reducing false‐negative results and decreasing the disease burden among the population.

The protocol of this systematic review was registered in the International Prospective Register of Systematic Reviews database (PROSPERO identifier: CRD42021236950). The report of this review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy Studies (PRISMA-DTA). 11 Reporting of the study conforms to broad EQUATOR guidelines. 12 

This systematic review included observational studies (including diagnostic test accuracy studies) reporting the number of subjects with suspected or confirmed SARS CoV-2 infection for whom the detection of viral RNA with RT-PCR was performed. We considered studies enrolling patients receiving an additional RT-PCR test as confirmation of viral infection after an initial negative result. Eligibility was not restricted by language, patient age or study setting. We included all types of RT-PCR kits and evaluated target genes.

We excluded studies that (1) did not report the number of subjects who received RT-PCR for further confirmation of SARS-CoV-2 infection following initial negative results, (2) aimed to validate a methodology, (3) evaluated sample specimens, (4) included case series and case reports, (5) included abstracts only, (6) were editorials and (7) included animal models.

In order to identify all primary studies, we searched the following electronic databases: Pubmed, Embase and Cochrane Central Register of Controlled Trials (CENTRAL). The search strategy was developed for PubMed (Table S1 ) and adapted for all databases; the adopted search strategy included the keywords "sars cov 2", "2019 ncov", "Real-Time Polymerase Chain Reaction", "COVID-19 Nucleic Acid Testing", "Reverse Transcriptase Polymerase Chain Reaction", "RT-PCR". Reference lists of potentially eligible studies were also screened. We limited the search to studies published in 2020-2021. The literature search was conducted by one investigator in February 2021.

One author screened titles and abstracts retrieved from the database searches and selected the studies for inclusion according to eligibility criteria. A second author checked the selection. Disagreements were resolved by consensus. From each included study, one author extracted the data necessary, and a second author validated the data. The following information was recorded: (1) study design type (i.e., cross-sectional, cohort); (2) study characteristics (authors, year, country); (3) characteristics of trial participants (i.e., sample size, age, gender, number of patients with COVID 19 diagnosis); (4) characteristics of RT-PCR test type, the cycle threshold value for positivity, target gene); (5) investigated outcomes (false-negative subjects). Disagreement between reviewers was resolved by consensus.

Two researchers independently assessed the methodological quality of the included studies. Diagnostic studies were evaluated with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. 13 Four domains were considered (patient selection, index test, reference standard and flow and timing), each rated in terms of their risk of bias and applicability to the research question. Risk of bias and applicability were judged as 'low', 'high' or 'unclear'. Any disagreements were resolved through discussion.

Cohort studies were assessed with an adapted National Institute of Health (NIH) Quality assessment tool for the NIH for Observational cohort and cross-sectional studies. 14 The ad hoc checklist included 12 questions. Possible answers included 'yes', 'no' 'unclear'. Each study was rated for overall quality as either good (≥7 'yes'), fair (≥4 'unclear') or poor (≥3 'no/unclear').

Two authors independently assessed the certainty of evidence for the primary outcomes using the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) framework methodology. 15, 16 Cross-sectional and prospective studies were initially considered at high quality but were downgraded according to: risk of bias, directness of evidence, consistency or imprecision. Directness refers to the link between test of interest and disease or populations evaluated. Consistency concerns the degree of homogeneity (direction and magnitude) of results across the different studies. Imprecision describes the grade of uncertainty across the effects estimate, in other words, the width of confidence intervals for diagnostic accuracy measurement. The quality of evidence for the main outcome of interest was rated as high, moderate, low or very low, depending on evaluated domains. 17 

Data were analysed with Stata V.15.1 (StataCorp). We presented data from eligible studies in evidence tables which were summarized using descriptive statistics. The percentage of false negatives was calculated using the Metaprop_ one, a command to perform meta-analysis of proportions in Stata. The false-negative rate was calculated together with the corresponding 95% confidence interval (CI) and a forest plot was generated to show the individual and pooled false-negative rate with 95% CI. Heterogeneity between primary studies was assessed using the Cochran's Q test and quantified with the I 2 statistic: I 2 <25% reveals low heterogeneity, ≥25% I 2 <75% indicates moderate heterogeneity, I 2 ≥75% expresses substantial heterogeneity. We performed subgroup analysis according to study design (accuracy or cohort studies), age of participants (adults or children), time interval between initial negative to positive RT-PCR (>3 days and ≤3 days) and type of specimen (nasopharyngeal, oropharyngeal or others). p-value <.05 was considered statistically significant.

The literature search, after the exclusion of duplicates and irrelevant records, identified 5,611 references. Of these, 5,530 were excluded because they did not meet the inclusion criteria. There were 81 studies considered eligible for inclusion and details were obtained from full texts. From full-text analysis, further 49 texts were excluded, leaving a total of 32 studies included in this systematic review ( Figure 1 ).

We included 32 studies (enrolling 146,454 participants), of whom 18,565 (12.7%) were COVID-19 confirmed cases. The number of participants ranged from 18 to 95,919. We included 15 cohort studies, 19, 27, [31] [32] [33] [34] 36, [38] [39] [40] [41] [42] [44] [45] [46] [47] [48] and 17 diagnostic accuracy studies, 18, [20] [21] [22] [23] [24] [25] [26] [28] [29] [30] 35, 37, 43, 49 details are reported in Table 1 . Participants' ages were reported in different ways: average mean ages ranged from 35 to 59 years, median ages ranged from 3 to 98 years. Overall, included studies reported that most patients were men (n = 9,821; 52%). The majority of studies were conducted in China (n = 19; 59%).

According to the study inclusion criteria, the presence of infection in all studies was confirmed after detection of SARS-CoV-2 RNA using RT-PCR assay, repeated following an initial negative result. The specimens collected for the RT-PCR assessment were heterogeneous among included studies; most studies reported nasopharyngeal swabs (n = 13) and oropharyngeal swabs (n = 7). The SARS-CoV-2 RNA was detected using different kits (n = 18 studies), and 11 studies reported the specific target gene, which was most frequently the ORF1ab gene (n = 8 studies) (Table 1 ).

We evaluated the 15 cohort studies with the QUADAS-2 tool. Eight studies were retrospective, five studies enrolled consecutive patients and in 10 studies the enrolment was unclear. In 6 studies, the authors were blinded to results of the index test and the defined threshold value. Because the interpretation of reference standards was objective, we evaluated this domain as low risk of bias for all studies. In 6 studies, the time interval between index test and reference standard was appropriate, but in all studies except one, all patients received the same reference standard ( Figure 2 , Table S2 ).

The 17 diagnostic accuracy studies were evaluated with the NIH tool. The overall methodological quality of included studies was classified as good in 12, fair in three and poor in two studies. All studies except three clearly defined the research question, the study population and the intervention. Twelve (70%) studies reported that the subjects were recruited from similar populations, 6 (35%) clearly described the inclusion and exclusion criteria, patients were enrolled consecutively in only 5 studies, and only 1 study provided a sample size justification. All studies clearly defined the outcome measures and described results adequately. The blinding of the outcome assessor was unclear in all studies, and 10 studies (59%) clearly described the statistical methods and considered an adequate follow-up ( Figure 3 , Table S3 ).

In quantitative analyses, we included all 32 studies reporting data from 18,565 patients affected by SARS-CoV-2. False-negative rates ranged from 2% 37 to 58%. 40 The summary estimate of the overall false-negative rate was 12% (95% CI 0.10-0.14; p < .001). We observed substantial heterogeneity among included studies (I 2 = 96%) (Table 2; Figure 4 ). F I G U R E 1 PRISMA flow diagram of the study selection process for this systematic review After subgroup analyses, we observed that the rate of false negatives was similar in diagnostic and cohort studies (14% and 12% respectively) with high heterogeneity among the included studies (Table 2, Figure S1 ). According to participant ages, the false-negative rates varied: 12% in studies enrolling adults only (n = 28), 9% in studies including both adults and children (n = 3), and 10% in a single study enrolling children only (n = 1). High heterogeneity was found among included studies (Table 2, Figure S2 ).

The false-negative rate was lower among studies who performed the second RT-PCR >3 days (2%) from the first RT-PCR, compared to studies performing test <3 days (28%), with high heterogeneity among included studies (76% vs. 96%) (Table 2, Figure S3 ). In the sensitivity analysis, excluding studies of He et al. 29 and Çinkooğluet al., 25 heterogeneity remained high (70% and 95%).

According to the specimen type used for RT-PCR assessment, false-negative rates were different. Most studies reported a mix of specimen types (n = 12) and the cumulative false-negative rate was 17%. False-negative rates for nasopharyngeal specimens (n = 5) were 3%, and for oropharyngeal swab (n = 3) was 16% (Table 2, Figure S4 ). However, 8 (25%) out of 32 included studies reporting the false-negative rate varied according to the number of days from symptom onset, decreased from 37% (day 3) 24 to 4% after 14 days. 49 The analysis by country showed a higher false-negative rate in studies conducted in China (24%) compared to other countries (4%), and the heterogeneity among included studies remains high (96% vs. 90%) (Table 2, Figure S5 ) probably due to the high prevalence of disease in this region at the beginning of 2020. 50 

Using the GRADE approach, we assessed the overall quality of evidence using the range of sensitivity to estimate the true value of false-negative rates. The quality of the evidence was downgraded for the risk of bias, indirectness and inconsistency and was judged overall to be very low (Table 3) . We subtracted 1 point for risk of bias for retrospective study design, 1 point for inconsistency as our meta-analysis showed substantial heterogeneity, and an additional 1 point for indirectness as the detection of falsenegative results was not the primary aim of many of the included studies.

To assess the impact of false-negative outcomes, we calculated a range of patients with misdiagnosis, based on disease prevalence among the population studies. We considered three different values of disease prevalence (10%, 30% and 50%) to describe the range of false-negative rates/1,000 tested subjects. Subject misdiagnosed according to prevalence were calculated to range from 2 to 58 for 10% prevalence, 6-164 for 30% prevalence and 10-290 for 50% prevalence (Table 3) .

This systematic review and meta-analysis, including data from 32 studies and more than 18,000 patients with SARS-Cov-2 infection, showed that the false-negative rate for RT-PCR detection of viral RNA for the COVID-19 diagnosis was 12% (range 2%-58%), with a very low certainty of evidence. Many of the included studies were affected by several sources of potential bias, especially related to patient selection, description of test characteristics and data analysis.

Usually, the diagnosis of COVID-19 is based on clinical and laboratory tests results, including chest X-ray and chest tomography revealing images suggestive of disease, and the research of antibodies against viral proteins or the viral RNA in respiratory samples using RT-PCR. This molecular method is considered the gold standard for COVID-19 diagnosis, and includes the RNA extraction from samples, followed by a reverse transcription step to convert RNA into complementary DNA (cDNA) that will undergo quantitative amplification using fluorescent probes that will recognize and hybridize to segments of the amplification products. This assay has the capacity to detect the viral nucleic acids in different sample types, making it the best diagnostic test available for adequate detection of infection. This test has high specificity, but the sensitivity is imperfect, 4 making questionable the accuracy of RT-PCR and the production of false-negative results that impact patients' management. The time window in which it is more likely to observe false-negative results is not clear.

Our meta-analysis showed high heterogeneity among included studies, which was not explained by some studies' characteristics, limiting the interpretation of summary estimates of the proportion of the false-negative results. We investigated plausible sources of heterogeneity, such as the type of study design, the specimen used, the age, the time to onset of symptoms, the country and the time between initial negative to positive RT-PCR, but not all included studies reported these details. We were able to find a small reduction of this variability in subgroups; studies collecting nasopharyngeal swabs, not Chinese studies and studies with the second RT-PCR performed >3 days from the initial tests, with false-negative rates of 3%, 4% and 2% respectively. However, we observed that the range of falsenegative rates decreased as times increased from disease onset. Wikramaratna et al. 51 using a statistical model, previously determined that the probability of obtaining a false-negative result in infected patients is affected by time since symptom onset and varying swab type sensitivities (nasopharyngeal swabs are more sensitive than oropharyngeal). The authors reported that the probability of incorrectly identifying an uninfected individual due to a false-negative test was considerably reduced if negative tests were repeated 24 h later. 51 In clinical practice, the accuracy of molecular tests is influenced by the stage of the disease 52 and the type and quality of sampling. 53 Viral RNA becomes detectable in the nasopharyngeal already from the first day of symptoms onset, reaches the peak within the first week from symptoms onset, and then decline. 52 However, the sensitivity estimated was 93% for broncho-alveolar lavage, 72% for sputum, 63% for nasal and 32% for throat swabs. 54 RT-PCR are often used to 'rule out' infection, especially among high-risk participants, such as exposed inpatients and health care workers: In these cases, a negative RT-PCR result is often interpreted as the absence of disease. 55 Using the GRADE approach, we evaluated the impact of the rate of false negative on 1,000 subjects tested, considering three different values of prevalence (10%, 30% and 50%). Even if the sensitivity is as high, the risk of falsenegative test results will be substantial, as testing becomes more widespread and the prevalence of COVID-19 infection rises. Otherwise, if the sensitivity of the test was poor, the number of false-negative results will be very high, even with low disease prevalence.

Studies included in this systematic review observed a wide range of false-negative RT-PCR results for SARS-CoV-2 infection according to a previous systematic review reporting that up to 36% of patients with COVID-19 may have an initial false-negative result. 56 Recent findings showed that these false-negative results may be determined by several factors, such as the type of specimen type, 57 temporal variation in viral shedding, 58 or diagnostic primer/probe mismatches with infecting virus sequence. 59 These false-negative rates have several implications on correct diagnosis, for public safety, health care worker safety, subsequent community transmission, and on health and economic policies to contain the SARS-Cov-2 pandemic. The magnitude of this concern is difficult to determine due to scarce information about test performance. Possible causes for false-negative tests could include (1) pre-analytical errors, which occur during the sampling procedure (i.e., skills of healthcare worker, patients cooperation) or during the sample transport (sample degradation), (2) laboratory errors due to scarce analytical sensibility, or presence of RT-PCR inhibitors, (3) imperfect timing of sampling during the course of the disease (if samples are taken in the early infection phase false-negative results are increased; variability due to the disease severity) due to the variability in viral shedding (viral nucleic acid in the tissue usually declines after the peak of symptoms).

In light of the data produced from this meta-analysis, the correct interpretation of RT-PCR results requires (1) clear definitions of pre-analytical risk levels prior to molecular testing; (2) cautious evaluation of negative results for subjects at high risk of SARS-CoV-2 infection; (3) second sample testing for subjects with high suspicion of SARS-Cov-2 infection following negative results; (4) the development of tests or combination of tests (detection of antibodies and viral genome) with high sensitivity to minimize the risk of false-negative results.

In order to be a reliable test for SARS-CoV-2, it is necessary that assays identifying viral genome should be accurate. RT-PCR sensitivity is estimated to range between 70% and 98%, while the specificity is approximately 95%, 60, 61 and for the diagnosis of other coronavirus infections, the overall summary of sensitivity and specificity was 89% and 99% respectively. 62 Likewise, the sensitivity and specificity of RT-PCR is not 100% for the determination of other pathogens, the sensitivity ranges from 65% This systematic review has a number of limitations that call for caution in result interpretation. Our meta-analyses were afflicted by substantial heterogeneity among included studies which were difficult to explain by studies' characteristics. Furthermore, due to very-low quality of evidence, the results should be interpreted with additional caution. Included studies were affected by several sources of potential bias, limiting their applicability. In addition, most included studies did not aim to evaluate the number of false-negative results of RT-PCT for COVID-19 diagnosis. Finally, included studies used various methods for SARS-CoV-2 testing, reducing the standardization for the molecular diagnosis of COVID-19. However, we assumed the second RT-PCR as a gold standard, and this could underestimate the rate of false-negative. RT-PCR is a test with high specificity, resulting in a small false-positive rate. 66, 67 Cohen et al. 68 showed evidence indicating that COVID-19 RT-PCR tests have a low but significant false-positive rate (between 0.2% and 0.9%) calculated with real-world data. These rates may seem low, but when the rate of infection is low, even a small false-positive rate can greatly diminish the reliability of positive test results. Although falsenegative results having a substantial impact on patients' management and influencing the propagation of the virus, the consequence of false-positive results could be significant. In fact, a false-positive test result can lead not only an unnecessary quarantine and contact tracing, but also an incorrect diagnosis, delaying or depriving patients of appropriate treatment. 68 A last challenge is related to time between first and second RT-PCR. Our analysis showed that the false-negative rate was lower among studies performing the second RT-PCR >3 days from the first RT-PCR, compared to studies performing test <3 days. This result is based on data reported by only 12 studies (37%) while the most of included studies not reported information about additional RT-PCR within the appropriate days to the first result, and not all patients enrolled in included studies received a second molecular testing.

In conclusion, up to 58% of COVID-19 patients may have an initial false-negative RT-PCR result, suggesting F I G U R E 2 Summary of risk of bias assessment with the QUADAS-2 tool. The x-axis represents the percentage of studies graded to a specific risk of bias: low, moderate or high risk of bias. The y-axis represents the 4 domains that were graded: patient selection, index test, reference standard, flow and timing F I G U R E 3 Summary of risk of bias assessment with the NIH tool. The x-axis represents the percentage of answers: yes, no, unclear. The y-axis reported the 12 questions considered in the evaluation. Q1: Was the research question or objective in this paper clearly stated?; Q2: Was the study population clearly specified and defined?; Q3: Were all the subjects selected or recruited from the same or similar populations (including the same time period)?; Q4: Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?; Q5: Were the cases consecutive?; Q6: Was a sample size justification, power description, or variance and effect estimates provided?; Q7: Was the intervention clearly described?; Q8: Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?; Q9: Were the people assessing the outcomes blinded to the participants' exposures/interventions?; Q10: Was the length of follow-up adequate?; Q11: Were the statistical methods well described?; Q12: Were the results well described? 

Novel coronavirus (SARS-CoV-2) Discharge criteria for confirmed COVID-19 cases -When is it safe to discharge COVID-19 cases from the hospital or end home isolation?

Diagnosing COVID-19: the disease and tools for detection

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19

Laboratory Diagnosis and Monitoring the Viral Shedding of SARS-CoV-2 Infection. Innovation (N Y)

Virological assessment of hospitalized patients with COVID-2019

SARSCoV-2 Viral load in upper respiratory specimens of infected patients

False negative tests for SARS-CoV-2 infection -challenges and implications

Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement

A catalogue of reporting guidelines for health research

QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies

NIH Study Quality Assessment Tools

GRADE guidelines: 21 part 1. Study design, risk of bias and indirectness in rating the certainty across a body of evidence for test accuracy

21 part 2. Inconsistency, Imprecision, publication bias and other domains for rating the certainty of evidence for test accuracy and presenting it in evidence profiles and summary of findings tables

Grading quality of evidence and strength of recommendations for diagnostic test and strategies

Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

Amplification of human βglucuronidase gene for appraising the accuracy of negative SARS-CoV-2 RT-PCR results in upper respiratory tract specimens

Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study

Accuracy of CT in a cohort of symptomatic patients with suspected COVID-19 pneumonia during the outbreak peak in Italy

Can chest CT features distinguish patients with negative from those with positive initial RT-PCR results for coronavirus disease (COVID-19)?

Early chest CT features of patients with 2019 novel coronavirus (COVID-19) pneumonia: relationship to diagnosis and prognosis

Chest CT of COVID-19 in patients with a negative first RT-PCR test: comparison with patients with a positive first RT-PCR test

CT imaging features of COVID-19 pneumonia: initial experience from Turkey

Sensitivity of chest CT for COVID-19: comparison to RT-PCR

Predicting patients with false negative SARS-CoV-2 testing at hospital admission: a retrospective multi-center study

CT in relation to RT-PCR in diagnosing COVID-19 in The Netherlands: a prospective study

Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China

The clinical sensitivity of a single SARS-CoV-2 upper respiratory tract RT-PCR test for diagnosing COVID-19 using convalescent antibody as a comparator

False negative rate of COVID-19 PCR testing: a discordant testing analysis

COVID-19 symptoms predictive of healthcare workers' SARS-CoV-2 PCR results

Testing for SARS-CoV-2: can we stop at 2?

Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19

Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT?

Occurrence and timing of subsequent severe acute respiratory syndrome coronavirus 2 reverse-transcription polymerase chain reaction positivity among initially negative patients

Comparison of the diagnostic efficacy between two PCR test kits for SARS-CoV-2 nucleic acid detection

A single-center, retrospective study of COVID-19 features in children: a descriptive investigation

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Characteristics and diagnosis rate of 5630 subjects receiving SARS-CoV-2 nucleic acid tests from Wuhan

RT-PCR tests for SARS-CoV-2 processed at a large Italian Hospital and false-negative results among confirmed COVID-19 cases

Consecutive false-negative rRT-PCR test results for SARS-CoV-2 in patients after clinical recovery from COVID-19

Coronavirus disease 2019: initial detection on chest CT in a retrospective multicenter study of 103 Chinese subjects

Frequency and distribution of chest radiographic findings in patients positive for COVID-19

Clinical Characteristics of Imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu Province: a multicenter descriptive study

False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence

Clinical characteristics of 194 cases of COVID-19 in Huanggang and Taian

Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCRnegative results for SARS-CoV-2

Imaging features and evolution on CT in 100 COVID-19 pneumonia patients in Wuhan, China

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges

Estimating the false-negative test probability of SARS-CoV-2 by RT-PCR

Interpreting diagnostic tests forSARS-CoV-2

Negative results in nucleic acid test of COVID-19 patients: assessment from the perspective of clinical laboratories

Detection of SARS-CoV-2 in different types of clinical specimens

The spectrum effect in tests for risk prediction, screening, and diagnosis

False-negative results of initial RT-PCR assays for COVID-19: a systematic review

Considerations for diagnostic COVID-19 tests

Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure

Mutations on COVID-19 diagnostic targets

Laboratory diagnosis of COVID-19

Interpreting a covid-19 test result

Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis

Diagnostic test accuracy of antigenaemia assay for PCR-proven cytomegalovirus infectionsystematic review and meta-analysis

Diagnostic accuracy of PCR alone and compared to urinary antigen testing for detection of legionella spp.: a systematic review

Diagnostic accuracy of in-house real-time PCR assay for Mycobacterium tuberculosis: a systematic review and meta-analysis

The impact of false positive COVID-19 results in an area of low prevalence

False-positive COVID-19 results: hidden problems and costs

Diagnosing SARS-CoV-2 infection: the danger of over-reliance on positive test results medRxiv

The authors thank Johanna Chester for her critical revision and editing assistance.

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. VP conceived and designed the systematic review. VP and AN wrote the protocol. VP designed and implemented the search strategy. VP and AN extracted and analysed the data. VP, AN and TT wrote the paper. All authors were involved in the critical revision of the intellectual content of the manuscript.

https://orcid. org/0000-0002-1800-0936